The Lawsuit That Forced FDA to Rethink Its Peptide Ban
FDA & Peptide Regulation
17 Peptides Restricted
In September 2023, the FDA added 17 peptides to its Category 2 restricted list without public comment or advisory committee review.
FDA Interim Policy on Compounding, 2023
FDA Interim Policy on Compounding, 2023
View as imageIn April 2024, a compounding pharmacy and a medical practice filed a lawsuit that would reshape how the FDA regulates peptide access in the United States. The case, brought by Evexias Health Solutions and FarmaKeio Pharmacy in the Northern District of Texas, argued that the FDA had bypassed legally required procedures when it restricted 17 peptides from compounding in September 2023. Understanding this legal challenge is essential context for the broader Category 2 classification and every regulatory development that followed.
The lawsuit did not argue that compounded peptides are inherently safe. It argued that the FDA broke its own rules in banning them. That distinction matters because the legal outcome turned entirely on administrative procedure, not pharmacology.
Key Takeaways
- The FDA added 17 peptides to its Category 2 restricted list in September 2023 without convening the Pharmacy Compounding Advisory Committee (PCAC) or accepting public comment
- Evexias Health Solutions and FarmaKeio Pharmacy filed suit in the Northern District of Texas in April 2024, alleging violations of the Administrative Procedure Act
- The September 2024 settlement required FDA to submit peptides for formal PCAC review in public meetings held October 29 and December 4, 2024
- Five peptides (AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank acetate) were removed from Category 2 on September 27, 2024
- Court filings indicate a final rule on the remaining substances is expected no later than March 14, 2027
- The case established that FDA cannot use interim guidance documents to impose de facto bans that bypass formal rulemaking
What FDA Did in September 2023
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can prepare medications from bulk drug substances when a licensed prescriber writes a patient-specific prescription.[1] Liu et al. (2025) reviewed this framework and noted that compounding, "when done following federal and state regulations, can fill an important need in our health care marketplace." The law creates a three-category system for bulk substances: Category 1 substances can be compounded, Category 2 substances present "significant safety risks" and cannot, and Category 3 substances are under review.
In September 2023, the FDA updated its interim guidance to move 17 peptides from various stages of review directly into Category 2. The affected substances included BPC-157, thymosin beta-4, AOD-9604, CJC-1295, ipamorelin, thymosin alpha-1, Selank, and others widely used by compounding pharmacies. The agency cited concerns about "risk for immunogenicity, peptide-related impurities, and limited safety-related information" as justification.
The peptides had not been reviewed by the Pharmacy Compounding Advisory Committee. No Federal Register notice had been published. No public comment period was offered. The FDA treated the Category 2 placement as a guidance update rather than a formal rulemaking action.
This matters because Section 503A(c)(1) of the FDCA specifically requires that, before developing the bulk drug substances list through regulation, the FDA must "convene and consult an advisory committee on compounding" unless the agency determines that skipping the committee "is necessary to protect the public health." The FDA made no such public health determination for the September 2023 peptide restrictions.
The Legal Theory: Administrative Procedure Act Violations
The core legal argument was straightforward. Under the Administrative Procedure Act (APA), federal agencies cannot impose binding restrictions through guidance documents that have not gone through notice-and-comment rulemaking. When the FDA categorized 17 peptides as Category 2 through an "interim guidance update," the plaintiffs argued it was exercising regulatory power while avoiding the procedural safeguards that constrain it.
The APA allows courts to set aside agency actions that are "arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law." The plaintiffs alleged that the FDA's peptide restrictions met this standard on multiple grounds: the agency provided no meaningful explanation for why each specific peptide posed safety concerns, bypassed the PCAC advisory process explicitly required by statute, and failed to offer any notice or opportunity for public comment.
Combs and Howard (2025) reviewed the legal landscape surrounding compounded peptide drugs and noted that both compounders and clinical practices "currently face significant legal risks" in a regulatory environment marked by rapid enforcement changes and jurisdictional complexity.[2] The authors found that the predominant off-label use of these drugs for weight loss, typically not covered by insurance, had created financial incentives that drew new market participants into a space where regulatory boundaries were poorly defined.
The lawsuit was filed in the Northern District of Texas, a federal court that has been receptive to APA challenges against federal agencies in recent years. The choice of venue was strategic. Federal courts in Texas have issued several significant rulings limiting agency authority when procedures were not followed, making the district favorable ground for an argument centered on procedural violations.
What the Settlement Required
In September 2024, the parties reached a settlement that legal analysts described as a partial win for compounders. The FDA did not concede that the peptides were safe for compounding. It conceded that it had not followed the required process for restricting them.
The settlement contained three key provisions. First, the FDA agreed to submit peptides for formal review by the Pharmacy Compounding Advisory Committee in public meetings. Two PCAC meetings were scheduled: October 29 and December 4, 2024. Second, stakeholders would have the opportunity to present evidence about patient use and clinical benefits of the restricted peptides. Third, the FDA committed to pursuing formal rulemaking rather than relying on guidance updates to restrict bulk drug substances.
On September 27, 2024, the FDA removed five peptides from Category 2: AOD-9604, CJC-1295, ipamorelin acetate, thymosin alpha-1, and Selank acetate (TP-7). The agency stated that the nominators who originally proposed these substances for the Category 2 list had withdrawn their nominations. This meant these five peptides reverted to a status where compounding pharmacies could legally prepare them.
The remaining peptides, including BPC-157 and thymosin beta-4, stayed on Category 2 pending PCAC review. Court filings reflect that a final rule on the remaining substances is expected by March 14, 2027. The case was administratively closed pending that anticipated publication.
The Quality Concerns Behind FDA's Position
The legal challenge was about procedure, not about whether peptide quality problems exist. On that question, the published evidence raises legitimate concerns.
McCall et al. (2026) analyzed 81,078 adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) between 2018 and 2024, comparing compounded versus non-compounded GLP-1 receptor agonists.[3] Of those reports, 707 involved compounded products. Compounded formulations showed reporting odds ratios of 48.92 for preparation errors, 19.00 for contamination, and 8.51 for manufacturing issues compared to brand-name versions. Hospitalization odds were 2.35 times higher for compounded products.
Those numbers need context. FAERS is a voluntary reporting system. Compounded products may attract disproportionate scrutiny during periods of heightened media attention and FDA enforcement. The study cannot prove causation. But the signal is large enough that dismissing it entirely would be premature.
Ashraf et al. (2024) conducted test purchases of semaglutide from illegal online pharmacies and found that all purchased vials were probable substandard products.[4] Visual inspection showed noncompliance in 59% to 63% of evaluated quality criteria. Measured semaglutide purity ranged between 7.7% and 14.37%, dramatically lower than the 99% claimed on labels. Endotoxin contamination was detected in all samples. The top 30 domains affiliated with illegal online pharmacies accumulated over 4.7 million visits between July and September 2023 alone.
The distinction between legally compounded products from licensed 503A and 503B pharmacies versus products sold illegally online is critical. The FDA's enforcement actions have sometimes blurred these categories, using quality problems in the illegal market to justify restrictions on legitimate compounding. DiStefano et al. (2025) documented 93 businesses in Colorado alone advertising compounded GLP-1 products for weight loss, with 41 of 93 websites making references to FDA approval in their descriptions of compounded products and 5 describing compounded products as "generic."[5] One website advertised a product compounded with BPC-157, a substance the FDA had classified as unsafe for compounding.
Administration Errors and Documentation Gaps
The quality question extends beyond manufacturing. Lambson et al. (2023) reported three cases of adverse drug events after incorrect administration of compounded semaglutide obtained from compounding pharmacies and an aesthetic spa.[6] Two patients self-administered 10-fold dosing errors. All three experienced prolonged nausea, vomiting, and abdominal pain lasting for days. One patient reported receiving a vial with syringes for self-administration and no pharmacist counseling on proper drug administration.
The issue is structural. Compounded peptides dispensed in multi-dose vials lack the safety features of prefilled manufactured pens, and variations in how dosing is communicated (milliliters, units, milligrams) contribute to patient confusion. Liu et al. (2025) reviewed the broader implications of the compounded semaglutide market and concluded that compounded products "may lack the quality controls historically seen with compounded formulations, resulting in risks for dosing errors and adverse health outcomes."[7]
Hendrix et al. (2025) found that among 153,044 patients using semaglutide or tirzepatide, only 8.2% had documented use of compounded formulations in their medical records.[8] Previous surveys estimated that 23% of patients using these medications received them from compounders. The gap suggests many patients access compounded peptides outside of coordinated primary care, limiting provider awareness and monitoring.
The Broader Peptide Quality Landscape
The quality concerns that animated the FDA's enforcement are not unique to compounded GLP-1 drugs. They reflect long-standing challenges in peptide manufacturing and quality control.
D'Hondt et al. (2014) published a comprehensive review of impurities found in peptide medicines, identifying deletion and insertion of amino acids from synthesis errors, diastereomeric impurities from racemization, contamination by unrelated peptides from "lack of appropriate GMP," and degradation products from storage instability.[9] These issues affect both commercial manufacturers and compounding facilities, though the scale of quality control resources differs enormously.
Rastogi et al. (2019) found that international pharmacopoeias lack harmonized quality standards for peptide drugs, with different countries applying different test methods and specifications to the same peptide substances.[10] This regulatory fragmentation means that the "quality standards" the FDA enforces for compounded peptides in the United States may not align with standards applied elsewhere, and no single global benchmark exists for what constitutes adequate peptide purity.
Currier et al. (2008) demonstrated that even commercial synthetic peptide libraries from established suppliers can contain contaminating peptides capable of producing false-positive results in vaccine trial assessments, with one sample containing approximately 1% by weight of an unrelated peptide from a completely different pathogen.[11] The finding underscores that peptide purity is a challenge across the entire pharmaceutical supply chain, not a problem unique to compounding pharmacies.
What Happened After the Settlement
The PCAC met on October 29 and December 4, 2024, to review several peptides that had been added to the Category 2 list. The substances reviewed at the December meeting included AOD-9604 (free base), CJC-1295 (multiple salt forms), and thymosin alpha-1 (free base and acetate). Stakeholders, including compounding pharmacies, physician groups, and patient advocates, presented testimony on clinical use and patient outcomes.
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of the 19 peptides previously on the Category 2 list would be moved back to Category 1 status. The reclassification announcement followed the legal precedent established by the Evexias settlement: the FDA acknowledged it needed proper evidentiary review before restricting compounding access.
The reclassification does not mean these peptides are FDA-approved drugs. Category 1 status means licensed compounding pharmacies can legally prepare them under physician prescription. The peptides still lack the randomized controlled trial data, manufacturing standardization, and post-market surveillance that FDA approval requires. The specific peptides moving back to Category 1 include substances like TB-500, CJC-1295, and ipamorelin, though final implementation details remain pending.
The legal precedent from the Evexias case extends beyond peptides. It reinforced that the FDA cannot use interim guidance documents to impose de facto bans on entire classes of substances without following the Administrative Procedure Act's notice-and-comment requirements. Any future attempt to restrict compounding access through informal policy updates rather than formal rulemaking will face an established legal framework for challenge.
The Bottom Line
The Evexias v. FDA lawsuit was a procedural challenge, not a safety argument. The court did not rule that compounded peptides are safe. It established that the FDA must follow its own statutory requirements when restricting access to bulk drug substances for compounding. The September 2024 settlement forced PCAC review, removed five peptides from Category 2, and set a precedent that informal guidance cannot substitute for formal rulemaking. Quality and safety concerns about compounded peptides remain supported by published evidence, but the legal framework now requires those concerns to be evaluated through transparent, public processes.